P E R S P E C T I V E
Pedigree, linkage and association studies are consistent with heritable variation for complex disease due to the segregation of genetic factors in families and in the population. In contrast, de novo mutations make only minor contributions to heritability estimates for complex traits. Nonetheless, some de novo variants are known to be important in disease etiology. The identification of risk-conferring de novo variants will contribute to the discovery of etiologically relevant genes and pathways and may help in genetic counseling. There is considerable interest in the role of such mutations in complex neuropsychiatric disease, largely driven by new genotyping and sequencing technologies. An important role for large de novo copy number variations has been established. Recently, whole-exome sequencing has been used to extend the investigation of de novo variation to point mutations in protein-coding regions. Here, we consider several challenges for the interpretation of such mutations in the context of their role in neuropsychiatric disease.
Several exome-based sequencing studies have been published for neuropsychiatric disorders (see ref. 1 for an overview), all focusing on families with sporadic cases of disease (those with a negative family history). Autism spectrum disorders (ASDs) have received the most attention, with five independent studies [2] [3] [4] [5] [6] ; in addition, one study has been published for mental retardation 7 and another three for schizophrenia [8] [9] [10] . A study reporting whole-genome sequencing of families with ASD or schizophrenia was also recently published 11 . These studies follow others that focused on de novo mutations in single or multiple candidate genes (for example, ref. 12), which we do not consider here. The largest studies so far for ASD have already yielded several candidate genes, highlighting the promise of 'de novo' experimental designs for the discovery of disease-relevant genes in neuropsychiatric disease. However, direct comparisons between exome studies are complicated by differences in experimental design (the use of matched family controls, population controls or a theoretical control), definition of the targeted exome, sequencing methodology and other features, such as whether insertions and deletions were considered along with point mutations.
The strongest evidence for an involvement of de novo mutations exists for ASD, based on the work of Iossifov et al. 2 and Sanders et al. 6 , which are the largest studies so far and the only ones to use a comprehensive sample of family controls (in the form of phenotypically discordant siblings). These studies, which, along with that of O'Roak et al. 5 , sequenced non-overlapping subsets of the Simons Simplex Collection (SSC), showed an enrichment of de novo gene-disrupting mutations (nonsense, splice site or frameshift) in probands with ASD compared to their unaffected siblings 2 , particularly in brain-expressed genes 6 . O'Roak et al. 5 used a similar approach but did not identify associations, perhaps owing to the small size of their control sample (n = 50). Two studies of schizophrenia by Xu et al. 9, 10 were the only others to incorporate controls, in the form of healthy parent-offspring trios. These studies found no difference in the de novo mutation rate in cases versus controls but observed a significant enrichment of putatively functional mutations in cases. Other studies, in lieu of control samples, have relied on comparisons to the theoretical expectation, based on previously reported mutation rates 3, 4, 7, 8 , to test for an enrichment of de novo mutation in disease. Inferences from these studies, although supportive of a role for de novo mutations, are inconsistent, most likely reflecting sampling effects and methodological differences between studies; these inconsistencies highlight the value of matched control samples, and in particular family controls, in studies of de novo mutation.
Two studies have shown that the protein products of genes harboring highly disruptive de novo mutations, together with those of previously identified ASD-relevant genes, exhibit greater connectivity in protein-protein interaction networks than would be expected by chance 3, 5 , providing further evidence for a role of de novo mutation in ASD. Iossifov et al. 2 also showed that genes harboring disruptive mutations in probands with ASD were strongly over-represented in the set of genes encoding factors known to interact with the FMRP gene product involved in fragile X mental retardation. All of the studies are consistent with the existence of a large number of genes contributing to these disorders, and, for ASD and schizophrenia, there is evidence for a correlation between paternal age and the number of observed de novo mutations per child 2, [4] [5] [6] 9, 11 . This observation, together with evidence for a paternal bias in the origin of de novo mutations 2, 3, 5, 11 , is consistent with an accumulation of mutations in the paternal germline 13 . Collectively, these findings represent solid evidence for a contribution from de novo protein-coding mutations in the etiology of neuropsychiatric disease. However, studies published P E R S P E C T I V E so far differ widely regarding the inferred penetrance of the identified mutations and the overall contribution of de novo variation to disease. The different conclusions reflect differences of interpretation, although true differences might exist between disorders. Incorrect inferences regarding the pathogenicity of de novo mutations can have serious consequences, both for genetic counseling 14 and in terms of misplaced investment in candidate genes for which disease associations cannot be replicated, a recurring problem in neuropsychiatric genetics. In this Perspective, we focus on several key challenges for the interpretation of results generated using de novo experimental designs, including the differentiation of risk-conferring mutations (particularly missense mutations) from those that are benign, the estimation of penetrance and the quantification of the relative importance of de novo and inherited variation.
Identifying de novo mutations conferring risk of disease A major challenge in the interpretation of the consequences of de novo protein-coding mutations in complex disease is that high levels of functional genetic variation have been shown to exist in the exomes of healthy individuals [15] [16] [17] [18] [19] . A typical exome harbors ~100 genedisrupting variants, including, on average, 2.8 severe, recessive diseaseassociated alleles in the heterozygous state 20 , less deleterious alleles contributing to individual phenotype and benign variation in redundant genes 21 . In addition, recent studies estimate that each person harbors approximately one de novo protein-altering mutation, both in ASD cases and controls 6 . The standard deviation of this number across individuals is also approximately one, so that finding two or even three de novo mutations in a single genome can occur by chance 6 . Furthermore, if there are up to 1,000 genes that can contribute to the risk of, say, ASD 6 , then the probability of observing a de novo mutation in 1 of those genes by chance is ~5%, assuming a total of 20,000 genes. Consequently, the simple presence of a provisionally functional de novo mutation in a proband, even one predicted to have severe effects, is not sufficient evidence that it contributes to risk 6 , let alone that it is sufficient to cause disease. Claims to this effect 4, 7, 8, 10 should be viewed with caution.
Multiple observations, either of the same mutation or of independent mutations in the same gene, are required to identify risk-conferring alleles or loci. The former is unlikely in exome studies for point mutations in complex disorders, whereas the latter is not unexpected. In theory, per-gene counts of functional de novo mutations in cases and controls should provide a means of identifying risk-associated genes. In practice, this approach has little statistical power because so many genes contribute to neuropsychiatric disorders that even the largest studies so far have yet to identify a gene harboring more than a few de novo mutations (excluding known regions of recurrent deletions and/or duplications that arise as a result of non-allelic homologous recombination 22, 23 ). Two alternative approaches to assessing whether recurrent de novo mutations in single genes are indicative of disease risk have been proposed. O'Roak et al. 5 compared the occurrence of multiple de novo events in CHD8, GRIN2B, LAMC3, NTNG1 and SCN1A to the expected number based on each gene's locus-specific mutation rate. Although all five genes were inferred to have a nominally significant excess of de novo events, only the excess in NTNG1 would survive correction for the testing of 14,363 brain-expressed genes. This represents a promising approach to the discovery of disease-causing genes, although it is important to be aware that gene-specific mutation rates are estimated with error (for instance, due to uncertainty in the human-chimpanzee divergence time used in the calculation).
Sanders et al. 6 proposed an alternative approach to identify genuine risk-associated mutations based on the empirical probability, across all brain-expressed genes, of observing multiple independent de novo point mutations in the same gene in unrelated individuals. Using simulations that accounted for sample size, gene size and GC content, they showed that two or more gene-disrupting mutations were unlikely to be observed by chance in the same brain-expressed gene in unrelated probands in their study, owing to the very low rates for de novo nonsense and splice-site mutations. A single gene (SCN2A) satisfied this threshold (≥2 independent gene-disrupting mutations) in their study 6 , but five others (CHD8, DYRK1A, GRIN2B, KATNAL2 and POGZ) have been identified by combining data across the four largest ASD studies 2, 3, 5, 6 . A seventh ASD-relevant gene (CUL3) has since been identified by the addition of whole-genome data from 44 Icelandic trios with ASD 11 . The identification of these genes represents landmark findings in ASD genetics, not only because genome-wide association studies (GWAS) in larger cohorts have not met with comparable success 24 (although we note that GWAS sample sizes for ASD have been smaller than for other neuropsychiatric disorders, such as schizophrenia and bipolar disorder, for which GWAS have been successful 25 ), but because the identified mutations, with obvious functional effects in single genes, provide valuable insights into disease biology.
An important consideration for future efforts to identify riskconferring genes using this approach is that the probability of a gene harboring multiple gene-disrupting de novo mutations by chance increases with sample size. Simulations from Sanders et al. 6 suggest that the probability of this occurring exceeds 5% in samples of greater than ~1,400 families. However, as the de novo mutation rate is higher in probands than in their siblings, the false discovery rate (FDR) for the occurrence of 2 gene-disrupting de novo mutations in probands is acceptable for sample sizes in excess of 3,000 families 6 . Clearly, the FDR will be lower still for the presence of three or more gene-disrupting mutations in the same brain-expressed gene. It is noteworthy, therefore, that the estimated frequencies of such mutations in probands in the ASD candidate genes CHD8 and SCN2A were 0.33% (5 mutations in ~1,500 cases) and 0.2% (3 mutations in ~1,500 cases), respectively 3 . These findings imply that, as sample sizes grow from hundreds to thousands of families, candidate genes will be identified by the presence of three or more de novo gene-disrupting mutations in probands.
We note that the simulations of Sanders et al. 6 , upon which these inferences are based, make a number of assumptions that might not hold for other ASD cohorts or for other neuropsychiatric disorders. For example, a key simulation parameter estimated from their data is the de novo mutation rate in probands. Similar studies of equivalent magnitude in schizophrenia and other disorders will be needed to confirm whether the approach will be more broadly successful. However, considering current evidence in ASD, family-based exome sequencing targeting de novo gene-disrupting mutations is a promising new paradigm for the discovery of disease-causing genes in complex neuropsychiatric disease 6 . The projected yield of genes conferring risk for ASD that will be identified in the entire SSC (~2,650 families with ASD) is large, ranging from ~25-50 (ref. 6) to >100 (ref. 2) , depending on the total number of ASD risk-conferring genes and the penetrance of individual mutations.
Interpreting the role of de novo missense mutations in disease
In contrast to the strong support for the involvement of gene-disrupting mutations in ASD, evidence that de novo missense mutations have a role is inconsistent. Sanders et al. 6 reported an enrichment of de novo missense mutations (both in isolation and in combination with genedisrupting mutations) in probands compared to unaffected siblings, particularly in brain-expressed genes, whereas Iossifov et al. 2 did not.
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Sanders et al. 6 found no evidence that the severity of missense mutations, as inferred from methods determining the degree of evolutionary conservation (for example, GERP) and other functional prediction methods (for example, PolyPhen-2), either singly or in combination, was informative with respect to risk. O'Roak et al. 5 , on the other hand, assumed that missense mutations in highly conserved positions were equivalent to gene-disrupting mutations. In the schizophrenia study by Xu et al. 10 , the strongest evidence for the involvement of de novo mutations came from a large excess of missense mutations in cases, a result that would not be expected if this class of variation did not have a role in disease. The role of de novo missense mutations in ASD and, more broadly, in neuropsychiatric disease is consequently unclear. Larger studies will be needed to resolve this issue because those published so far have been small and have had limited power to detect (or conversely rule out) realistic contributions from de novo missense mutations 2, 6 . However, given that a large proportion of de novo missense mutations are predicted to be mildly deleterious 26 and that there is evidence for weak purifying selection on coding sequences in human populations 16, 18, 19 , we anticipate that data from larger family-based exome studies of neuropsychiatric disorders will converge on a significant role for de novo missense mutations.
A number of genes have been found to harbor two de novo missense mutations in unrelated probands with ASD, but this is not sufficient evidence to implicate them in disease. The probability of observing multiple independent mutations by chance is higher for missense mutations relative to gene-disrupting mutations because the mutation rate is ~20-fold higher 6 . As a consequence, the FDR for the identification of multiple missense mutations is strongly dependent on the sample size and underlying genetic model. For studies published so far, involving ~200-300 families, 3 independent missense mutations are required to implicate a gene in disease, and 4 are needed as sample size increases, depending on the total number of risk-conferring genes. That no gene has been found to harbor this number of de novo missense mutations might also be a consequence of inadequate sample size, as the effect size of missense mutations is predicted to be modest. A salient point, given the primacy of the mutation rate in determining whether recurrent de novo mutations point to genuine disease genes, is that the assumption of a single mutation rate for missense mutations overlooks substantial fine-scale and context-dependent variation in the human mutation rate. The best-known example is the 10-to 20-fold higher rate of C>T and G>A transition mutations at CpG dinucleotides 11 , which occurs because cytosine residues in CpGs are frequently methylated and methylcytosines are prone to undergo spontaneous deanimation to thymine 27 . Other examples of mutation rate variation have also been described 28, 29 . Given that this variation is known to exist, more sophisticated analyses that differentiate missense (and, for that matter, genedisrupting) mutations into different classes (for example, mutations in CpG verses non-CpG dinucleotides 11 ) and that interpret recurrence in the context of the expected mutation rate for that subset of mutations may be insightful. Finally, gene-based testing in case-control exome studies may also be an efficient means of identifying risk-conferring genes on the basis of segregating missense variation 30, 31 . Such studies benefit from a twofold lower sequencing cost in comparison to familybased studies focused on de novo mutations in probands and unaffected siblings, although preliminary studies indicate that very large sample sizes will be required for success 30 .
Estimating the penetrance of de novo protein-coding mutations
The distribution of effect sizes for de novo protein-coding mutations in neuropsychiatric disorders is yet to be determined. The expectation is that these variants will have moderate to large effect sizes, as this is the case for identified recurrent copy number variations (CNVs) 32 . Several of the studies mentioned in this Perspective favor models involving highly penetrant mutations. For example, Vissers et al. 7 proposed that de novo point mutations of large effect, in combination with de novo CNVs, "could explain the majority of all mental retardation cases in the population, " and Xu et al. 10 stated that de novo mutations, including newly arisen CNVs, "account for more than half of the sporadic cases of schizophrenia." In ASD, Iossifov et al. 2 support a model in which a third or more of all sporadic cases harbor causal de novo mutations 33 . These statements imply that single de novo mutations might be sufficient to cause disease, consistent with the model of extreme genetic heterogeneity for complex disease advocated by some 34 . Although the existence of some fully penetrant mutations is a possibility, particularly for mental retardation (for example, refs. 35, 36) , ASD (for example, ref. 37 ) and other disorders with documented monogenic forms (with schizophrenia and bipolar disorder being prominent exceptions 25 ), the suggestion that a large proportion of cases for any common neuropsychiatric disorder are due to highly penetrant de novo events is not consistent with empirical evidence of the recurrence risk to relatives 38, 39 (a point we discuss in more detail in the next section and in the Supplementary Note). More specifically, there is currently no way to determine which, if any, de novo protein-coding mutations are sufficient to cause disease because no single event has been observed more than once. This is in contrast to documented recurrent CNVs, many of which have been observed in multiple cases and controls.
The currently available data in ASD are sufficient for effect size estimates of broad classes of mutations (for example, gene-disrupting variations), and are consistent with more modest average penetrance. Sanders et al. 6 used data from matched family controls to show that the odds ratio (OR) for gene-disrupting mutations relative to silent mutations in brain-expressed genes in ASD cases compared to unaffected siblings was 5.65 (95% confidence interval (CI) = 1. 44-22.20) , similar to that of documented multigenic CNVs 40 . Estimates for de novo missense mutations were lower (OR = 2.06, 95% CI = 1.10-3.85) but nonetheless greater than for identified common variants 24 . These estimates are likely to represent a mix of effects from risk-conferring and benign mutations, and, thus, individual risk-conferring mutations may have larger effects 6 . Nonetheless, they imply that the majority of individual de novo mutations in ASD are insufficient to cause disease and therefore must act in combination with other risk factors (including inherited variation and environmental factors) to generate a disease phenotype. This is a crucial point that in some studies seems underappreciated 2, 7, 10, 33 , with important implications for the clinical application of exome sequencing (for example, ref. 41 ). The field awaits larger exome studies, including studies in multigenerational pedigrees, which should help to refine the distribution of effect sizes for de novo protein-coding mutations in ASD and other neuropsychiatric disorders.
Quantifying the contribution of de novo mutations to disease
It is now clear that neuropsychiatric disorders are underpinned by a large number of genes 42, 43 and that affected individuals harbor multiple risk factors, but the relative contributions of de novo and inherited variations are yet to be established. The exome studies that are the focus of this Perspective, although unanimous in establishing a role for de novo mutations in neuropsychiatric disorders, differ widely in their conclusions regarding the magnitude of their contribution to disease. As noted above with respect to effect size, three studies in particular conclude that this contribution is very substantial and that de novo mutations (including CNVs) may account for a large npg P E R S P E C T I V E proportion of all cases of ASD 2 , mental retardation 7 and schizophrenia 10 . Other studies have proposed an oligogenic (or 'multi-hit') model in ASD 4, 5 , whereby single de novo mutations combine with one or a few deleterious rare inherited variants to confer disease. In contrast, Neale et al. 3 and Sanders et al. 6 favor a more limited contribution, with mutations having effect sizes similar to those of known CNVs in no more than 10-20% of cases. Clearly, more data will be required to resolve which of these models (if any) is correct, but the suggestion that de novo mutations account for a large proportion of the total liability for these disorders is hard to reconcile with heritability estimates that are consistently high (~80% for ASD 38 and schizophrenia 44 ). A majority of de novo mutations are unique to a single individual and thus will not contribute to the observed recurrence risk to relatives or to the estimate of heritability. Exceptions include de novo mutations originating in the parental germline that are shared by monozygotic twins or by siblings (including dizygotic twins) in the case of germline mosaicism. If, as is suspected, mosaicism is relatively infrequent (for example, Iossifov et al. 2 reported the same mutation in ~1 in 50 sets of siblings), then the effect of de novo variants on the estimate of heritability will be primarily through their contribution to recurrence risk for monozygotic twin pairs, and only if heritability estimates from pedigree data include monozygotic twins. Evidence from mutation accumulation experiments, data on recurrence risk to relatives and theory suggest that this contribution is likely to be small, on the order of ~1% (Supplementary Fig. 1 and Supplementary Note). The primary contribution of de novo mutations to variance of disease risk in the population will usually be partitioned into the non-heritable component, and, because heritability estimates for neuropsychiatric disorders are so high (~80%), there is a ceiling on the total contribution from de novo mutations (Supplementary Note).
Conclusions
Recent family-based exome studies targeting de novo mutations in autism [2] [3] [4] [5] [6] , mental retardation 7 and schizophrenia [8] [9] [10] are the likely forerunners of many similar efforts across the breadth of neuropsychiatric disease and complex disease in general. Studies considered in this Perspective support a substantial role for de novo proteincoding mutations in neuropsychiatric disease, particularly in ASD, which has been the focus of the largest studies so far. The approach established by Sanders et al. 6 , whereby the likelihood that de novo mutations are risk conferring is assessed in terms of the empirical probability of observing recurrent mutations in the same gene, has identified a number of promising candidate genes for ASD. These discoveries are particularly important because, in contrast to GWAS and the majority of CNV findings, they involve readily interpretable mutations in single genes and thus provide immediate biological insight into disease mechanisms. Although we are mindful that equivalent success is yet to be demonstrated for other disorders and that the method is dependent on assumptions that may not always be appropriate, it is clear that well-powered family-based exome sequencing studies targeting de novo mutations represent a promising new paradigm for the discovery of disease-relevant genes in neuropsychiatric disease. We anticipate that larger studies of this type will make an important contribution to progress in the field.
The emerging empirical evidence on the genetic architecture of neuropsychiatric disease (and those of other complex diseases) from whole-exome sequencing studies (including those reviewed here), CNV analysis and GWAS is one of multiple genetic factors and environmental factors that jointly increase risk of disease. Genetic risk factors include de novo CNVs, point mutations and indels, rare inherited mutations and CNVs, and both common and rare inherited polymorphisms. This spectrum of variation likely spans both protein-coding and functional noncoding regions. The latter are poorly represented in published exome studies, but this is likely to change as the field moves toward whole-genome sequencing and as findings from the Encyclopedia of DNA Elements (ENCODE) Project enable detailed annotation of functional noncoding elements 45 . The key challenges for the field are to clarify and quantify the relative importance of the different classes of variation, which may differ between disorders, and to understand how they act together to cause disease. Very large studies, including family-based exome and/or whole-genome sequencing, as well as complementary case-control approaches, will be required to address these challenges 31 . Studies that leverage transcriptome-wide expression data to provide insight into the functional consequences of de novo mutations, as has been reported for de novo CNVs in ASD 46 , are also likely to contribute.
In this Perspective, we have addressed a number of challenges for interpreting the role of de novo mutations in neuropsychiatric disease. A clear message from studies so far is that the number and predicted severity of de novo mutations identified in a single individual is insufficient evidence for causality 6 . The burden of proof for causality for a single de novo mutation must be set high because incorrect inferences can have serious consequences for affected individuals and their families 14 , as well as doing the field a disservice, owing to misplaced investment in candidate genes that do not replicate. This burden of proof (beyond reasonable doubt) is likely to be case specific and may include knowledge of recurrent genedisrupting de novo mutations in the same gene in unrelated individuals with the same disorder, together with functional evidence that is consistent with both a direct effect of the mutation 46 and the observed clinical phenotype. The curation of de novo protein-coding mutations and their associated phenotypes in databases, as has been instigated for CNVs 14, 47 , will be essential to identify the genotypephenotype correlations needed for robust clinical interpretation of de novo mutations in exome sequencing studies 48 .
Note: Supplementary information is available in the online version of the paper.
